We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.
- Authors
Hakjun Hyun; Eliel Nham; Hye Seong; Jin Gu Yoon; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Sun Kyung Yoon; Se-Jin Park; WonSeok Gwak; June-Woo Lee; Byoungguk Kim; Joon Young Song
- Abstract
Background: The assessment of long-term humoral and cellular immunity postvaccination is crucial for establishing an optimal vaccination strategy. Methods: This prospective cohort study evaluated adults (=18 years) who received a BA.4/5 bivalent vaccine. We measured the anti-receptor binding domain immunoglobulin G antibody and neutralizing antibodies (NAb) against wild-type and Omicron subvariants (BA.5, BQ.1.1, BN.1, XBB.1 and EG.5) up to 9 months postvaccination. T-cell immune responses were measured before and 4 weeks after vaccination. Results: A total of 108 (28 SARS-CoV-2-naïve and 80 previously infected) participants were enrolled. Anti-receptor binding domain immunoglobulin G (U/mL) levels were higher at 9 months post-vaccination than baseline in SAR-CoV-2-naïve individuals (8,339 vs. 1,834, p<0.001). NAb titers against BQ.1.1, BN.1, and XBB.1 were significantly higher at 9months post-vaccination than baseline in both groups, whereas NAb against EG.5 was negligible at all time points. The T-cell immune response (median spot forming unit/106 cells) was highly cross-reactive at both baseline (wild-type/BA.5/XBB.1.5, 38.3/52.5/45.0 in SARS-CoV-2-naïve individuals; 51.6/54.9/54.9 in SARS-CoV-2-infected individuals) and 4 weeks post-vaccination, with insignificant boosting post-vaccination. Conclusion: Remarkable cross-reactive neutralization was observed against BQ.1.1, BN.1, and XBB.1 up to 9 months after BA.4/5 bivalent vaccination, but not against EG.5. The T-cell immune response was highly cross-reactive.
- Subjects
CELLULAR immunity; HUMORAL immunity; SARS-CoV-2 Omicron variant; COVID-19 vaccines; IMMUNOGLOBULIN G
- Publication
Frontiers in Immunology, 2024, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2024.1385135